 "Sun Pharma")
The US Food and Drug Administration’s (US FDA’s) approval to Sun Pharmaceutical Industries’ plaque psoriasis drug tildrakizumab, or tildra, has given a push to the company’s speciality foray.
The drug, developed in partnership with Merck, is expected to be launched in early FY19.
Given pricing pressure in the US on its generic portfolio, Sun Pharma has been focusing on bringing to the market its next growth vehicle in the form of speciality drugs that are difficult to make, administer and typically fetch higher margins due to limited competition.
Analysts expect tildra, branded as Ilumya, to see a
The drug, developed in partnership with Merck, is expected to be launched in early FY19.
Given pricing pressure in the US on its generic portfolio, Sun Pharma has been focusing on bringing to the market its next growth vehicle in the form of speciality drugs that are difficult to make, administer and typically fetch higher margins due to limited competition.
Analysts expect tildra, branded as Ilumya, to see a
